Your browser doesn't support javascript.
loading
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
West, R L; Zelinkova, Z; Wolbink, G J; Kuipers, E J; Stokkers, P C F; van der Woude, C J.
Affiliation
  • West RL; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. r.west@erasmusmc.nl
Aliment Pharmacol Ther ; 28(9): 1122-6, 2008 Nov 01.
Article in En | MEDLINE | ID: mdl-18691349
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Tumor Necrosis Factor-alpha / Anti-Inflammatory Agents / Antibodies, Monoclonal Type of study: Observational_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2008 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Tumor Necrosis Factor-alpha / Anti-Inflammatory Agents / Antibodies, Monoclonal Type of study: Observational_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2008 Document type: Article Affiliation country: Netherlands